Abstract
The development of chalcones as antimitotic agents has led to the design of other analogues able to interact with tubulin and inhibit its assembly into microtubules. This activity has also been associated with their anti-vascular activity. This review focuses on the development of chalcones and related analogues as antimitotic agents.
Keywords: Chalcone, tubulin, microtubule, antimitotic, cytotoxic
Anti-Cancer Agents in Medicinal Chemistry
Title: Antimitotic Chalcones and Related Compounds as Inhibitors of Tubulin Assembly
Volume: 9 Issue: 3
Author(s): Sylvie Ducki
Affiliation:
Keywords: Chalcone, tubulin, microtubule, antimitotic, cytotoxic
Abstract: The development of chalcones as antimitotic agents has led to the design of other analogues able to interact with tubulin and inhibit its assembly into microtubules. This activity has also been associated with their anti-vascular activity. This review focuses on the development of chalcones and related analogues as antimitotic agents.
Export Options
About this article
Cite this article as:
Ducki Sylvie, Antimitotic Chalcones and Related Compounds as Inhibitors of Tubulin Assembly, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (3) . https://dx.doi.org/10.2174/1871520610909030336
DOI https://dx.doi.org/10.2174/1871520610909030336 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Breath Analysis Using SIFT-MS to Assess Metabolic Status in Patients After Gastro-oesophageal Cancer Surgery- a Pilot Study
Current Analytical Chemistry Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Current Cardiology Reviews Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets Preliminary Studies on the Activity of Mixed Polyphenol-Heterocyclic Systems Against B16-F10 Melanoma Cancer Cells
Medicinal Chemistry Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine A Virtual Screening Approach for the Identification of High Affinity Small Molecules Targeting BCR-ABL1 Inhibitors for the Treatment of Chronic Myeloid Leukemia
Current Topics in Medicinal Chemistry Other Potential Therapeutic Targets in Thyroid Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies
Current Drug Targets CD45 Regulated Signaling Pathways
Current Topics in Medicinal Chemistry Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Synthesis and Anticancer Activity of Some 1H-inden-1-one Substituted (Heteroaryl)Acetamide Derivatives
Letters in Drug Design & Discovery Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)
Current Cancer Drug Targets Effects of Natural Products on Mcl-1 Expression and Function
Current Medicinal Chemistry Proteomics in Acute Myelogenous Leukaemia (AML): Methodological Strategies and Identification of Protein Targets for Novel Antileukaemic Therapy
Current Drug Targets